Barbara Schaeffler

1.2k total citations · 2 hit papers
15 papers, 862 citations indexed

About

Barbara Schaeffler is a scholar working on Psychiatry and Mental health, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Barbara Schaeffler has authored 15 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 8 papers in Physiology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Barbara Schaeffler's work include Migraine and Headache Studies (13 papers), Sympathectomy and Hyperhidrosis Treatments (5 papers) and Trigeminal Neuralgia and Treatments (4 papers). Barbara Schaeffler is often cited by papers focused on Migraine and Headache Studies (13 papers), Sympathectomy and Hyperhidrosis Treatments (5 papers) and Trigeminal Neuralgia and Treatments (4 papers). Barbara Schaeffler collaborates with scholars based in United States, Denmark and Australia. Barbara Schaeffler's co-authors include Susan Pederson, Roger Cady, Joe Hirman, Jeff Smith, Brent Allan, David M. Biondi, Richard B. Lipton, Peter J. Goadsby, Messoud Ashina and Joel R. Saper and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Frontiers in Immunology.

In The Last Decade

Barbara Schaeffler

14 papers receiving 847 citations

Hit Papers

Efficacy and safety of eptinezumab in patients with chron... 2020 2026 2022 2024 2020 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of eptinezumab in patients with chronic migraine
    2020 273 citations Richard B. Lipton, Peter J. Goadsby et al. Neurology profile →
  2. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
    2020 264 citations Messoud Ashina, Joel R. Saper et al. Cephalalgia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Schaeffler United States 10 790 572 335 68 51 15 862
Yngve Hallström United States 8 807 1.0× 492 0.9× 265 0.8× 137 2.0× 70 1.4× 11 964
Katharina Kamm Germany 10 518 0.7× 320 0.6× 195 0.6× 46 0.7× 72 1.4× 26 640
David Doležil United States 10 914 1.2× 657 1.1× 336 1.0× 103 1.5× 90 1.8× 27 992
Jan Klatt United States 18 1.3k 1.6× 926 1.6× 490 1.5× 134 2.0× 120 2.4× 43 1.4k
Jo Bonner United States 8 782 1.0× 522 0.9× 297 0.9× 63 0.9× 94 1.8× 11 868
Tricia Blankenbiller United States 4 893 1.1× 620 1.1× 367 1.1× 87 1.3× 102 2.0× 8 962
Xiaoping Ning United States 12 823 1.0× 469 0.8× 239 0.7× 83 1.2× 61 1.2× 48 887
Sabrina Khan Denmark 10 454 0.6× 229 0.4× 141 0.4× 70 1.0× 58 1.1× 20 597
Jesper Filtenborg Tvedskov Denmark 10 822 1.0× 483 0.8× 315 0.9× 33 0.5× 129 2.5× 27 936
Ernesto Aycardi United States 14 1.2k 1.5× 846 1.5× 509 1.5× 108 1.6× 136 2.7× 32 1.4k

Countries citing papers authored by Barbara Schaeffler

Since Specialization
Citations

This map shows the geographic impact of Barbara Schaeffler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Schaeffler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Schaeffler more than expected).

Fields of papers citing papers by Barbara Schaeffler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Schaeffler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Schaeffler. The network helps show where Barbara Schaeffler may publish in the future.

Co-authorship network of co-authors of Barbara Schaeffler

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Schaeffler. A scholar is included among the top collaborators of Barbara Schaeffler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Schaeffler. Barbara Schaeffler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Smith, Timothy R., Egilius L.H. Spierings, Roger Cady, et al.. (2021). Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. The Journal of Headache and Pain. 22(1). 16–16. 34 indexed citations
2.
Pederson, Susan, David M. Biondi, Brent Allan, et al.. (2021). Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine. Frontiers in Immunology. 12. 765822–765822. 2 indexed citations
3.
Kudrow, David, Roger Cady, Brent Allan, et al.. (2021). Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurology. 21(1). 126–126. 63 indexed citations
4.
Baker, Brian, Barbara Schaeffler, Joe Hirman, et al.. (2021). Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. Endocrinology Diabetes & Metabolism. 4(2). e00217–e00217. 9 indexed citations
5.
Silberstein, Stephen D., Merle L. Diamond, Nada Hindiyeh, et al.. (2020). Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study. The Journal of Headache and Pain. 21(1). 120–120. 72 indexed citations
6.
Lipton, Richard B., Peter J. Goadsby, Jeff Smith, et al.. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 94(13). e1365–e1377. 273 indexed citations breakdown →
7.
Smith, Timothy R., Marina Janelidze, Roger Cady, et al.. (2020). Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study. Clinical Therapeutics. 42(12). 2254–2265.e3. 41 indexed citations
8.
9.
Baker, Brian, Barbara Schaeffler, Martin Béliveau, et al.. (2020). Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacology Research & Perspectives. 8(2). e00567–e00567. 48 indexed citations
10.
Ashina, Messoud, Joel R. Saper, Roger Cady, et al.. (2020). Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 40(3). 241–254. 264 indexed citations breakdown →
11.
Dodick, David W., Timothy R. Smith, Roger Cady, et al.. (2019). Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials (S17.004). Neurology. 92(15_supplement). 3 indexed citations
12.
13.
14.
15.
Ciuleanu, Tudor–Eliade, Y. Demidchik, С. В. Орлов, et al.. (2010). Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). 7002–7002. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yngve Hallström Breakdown of academic impact, for papers by Katharina Kamm Breakdown of academic impact, for papers by David Doležil Breakdown of academic impact, for papers by Jan Klatt Breakdown of academic impact, for papers by Jo Bonner Breakdown of academic impact, for papers by Tricia Blankenbiller Breakdown of academic impact, for papers by Xiaoping Ning Breakdown of academic impact, for papers by Sabrina Khan Breakdown of academic impact, for papers by Jesper Filtenborg Tvedskov Breakdown of academic impact, for papers by Ernesto Aycardi
Rankless by CCL
2026